Sunil Paliwal

At Stevens, Dr. Paliwal's research is focused on ML and AI driven drug discovery and synthesis to develop medicines to treat infectious disease such as COVID-19 and Celiac disease.

Dr. Sunil Paliwal came to Stevens on September 01, 2015 after working for several years in pharmaceutical industry, Schering-Plough and later at Merck. He has 15 years of experience in pharmaceutical industry and 9 years of experience in academia. He has been co-inventor in 40 patents and has published 17 papers. In addition to teaching several courses at Stevens, Dr. Paliwal is also actively engaged in mentoring and conducting research with several undergraduate and graduate students. The research work resulted in 13 poster presentations by the students in prestigious internal and external meetings and conferences, two patent filings, one publication.

Dr. Paliwal has 15 years experience as a medicinal chemist and project leader performing research in drug discovery for Schering-Plough Research Institute and at Merck where he was Director of Exploratory Medicinal Chemistry. His expertise is in developing small molecules to treat oncology, neurological, cardiovascular and inflammation diseases.

Dr. Paliwal’s preclinical discovery includes leading teams to discover early drug hits from high-throughput screening (HTS) involving the screening of millions of compounds, optimization of hits and developing program leads through evaluations of chemical structure and biological data to develop key structural-activity-relationships (SAR). Dr. Paliwal’s research experience also include optimization of the DMPK and biological data of the leads to deliver clinical compounds with optimal DMPK/pharmacological properties. He is co-inventor of a drug (Varubi®) and has progressed two other compounds into clinic to treat cancer and neurological diseases.

Provided medicinal chemistry expertise to biotech and academic institutions.

Co-inventor of the drug (Varubi®).

Paliwal, S.; Cornwell, S.; Sabio, M.; Saremi, L.; Casillas, C.; Windsor, W.; Tolias, P. “Spiro compounds as RAS inhibitors”, Patent Number: 2022040469
Paliwal, S.; Sabio, M.; Saremi, L.; Russo, C.A.; Zhao, H.; Huang, K.-S.; Tolias, P. “ERK inhibitors for cancer therapy”. Patent Number: WO 2021216777
Mcelroy, W.; Li, G.; Ho, G.; Zheng, T.; Paliwal, S.; Seganish, W.M.; Tulshian, D.; Lampe, J.; Methot, J.L.; Zhou, H.; Altman, M.D.; Zhu, L.“Amidopyrazole inhibitors of interleukin receptor-associated kinases” WO 2012129258.

CH 115, CH 580, CH 412, BIO 682, CH 800